Agios Pharmaceuticals (AGIO) Long-Term Investments (2013 - 2026)

Agios Pharmaceuticals has reported Long-Term Investments for 14 years, with the latest figure at $308.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 41.94% year-over-year to $308.5 million; the trailing twelve-month figure through Mar 2026 stood at $308.5 million (down 41.94% YoY), and the FY2025 full-year result was $310.0 million, down 51.43% from the prior year.
• Long-Term Investments for Q1 2026 stood at $308.5 million, down from $310.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $655.9 million in Q3 2024, with the low at $29.4 million in Q4 2023.
• Historically, Long-Term Investments has averaged $309.4 million across 5 years, with a median of $298.4 million in 2022.
• Annual changes were most pronounced in 2023 — Long-Term Investments slumped 90.62% — and 2024, when it soared 2068.58%.
• Agios Pharmaceuticals' Long-Term Investments stood at $313.9 million in 2022, then tumbled by 90.62% to $29.4 million in 2023, then soared by 2068.58% to $638.3 million in 2024, then tumbled by 51.43% to $310.0 million in 2025, then declined by 0.5% to $308.5 million in 2026.
• The last three Long-Term Investments figures came in at $308.5 million (Q1 2026), $310.0 million (Q4 2025), and $304.3 million (Q3 2025), per Business Quant data.